1 / 3

S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial

S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial. Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study. www.shift-study.com. Tavazzi L, et al. Eur J Heart Fail. 2013;15(11):1296-1303.

kenna
Télécharger la présentation

S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Systolic Heart failure treatment withthe Ifinhibitor ivabradineTrial Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study www.shift-study.com TavazziL, et al. Eur J Heart Fail.2013;15(11):1296-1303

  2. Age does not limit the efficacy of ivabradine in patients with CHF and LVSD TavazziL, et al. Eur J Heart Fail.2013;15(11):1296-1303 www.shift-study.com

  3. Age does not limit the efficacy of ivabradine in patients with CHF and LVSD Incidence of CV death or hospitalization for worsening HF in patients in the lowest and highest quartiles of age • In very elderly patients (≥75 years; n=722), ivabradine reduces CV death (16% vs 22%; P=0.048) and HF death (4% vs 8% P=0.019) TavazziL, et al. Eur J Heart Fail.2013;15(11):1296-1303 www.shift-study.com

More Related